These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 9809930)

  • 1. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.
    Pepine CJ; Handberg-Thurmond E; Marks RG; Conlon M; Cooper-DeHoff R; Volkers P; Zellig P
    J Am Coll Cardiol; 1998 Nov; 32(5):1228-37. PubMed ID: 9809930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).
    Sava RI; Chen YE; Smith SM; Gong Y; Cooper-DeHoff RM; Keeley EC; Pepine CJ; Handberg EM
    J Womens Health (Larchmt); 2020 Feb; 29(2):158-166. PubMed ID: 31403360
    [No Abstract]   [Full Text] [Related]  

  • 4. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
    Bakris GL; Cooper-Dehoff RM; Zhou Q; Kupfer S; Champion A; Pepine CJ;
    Am J Cardiovasc Drugs; 2007; 7 Suppl 1():25-9. PubMed ID: 19845074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).
    Zineh I; Cooper-Dehoff RM; Wessel TR; Arant CB; Sleight P; Geiser EA; Pepine CJ
    Clin Cardiol; 2005 Jul; 28(7):321-8. PubMed ID: 16075824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
    Bakris GL; Gaxiola E; Messerli FH; Mancia G; Erdine S; Cooper-DeHoff R; Pepine CJ;
    Hypertension; 2004 Nov; 44(5):637-42. PubMed ID: 15381674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
    Cooper-DeHoff RM; Handberg EM; Mancia G; Zhou Q; Champion A; Legler UF; Pepine CJ
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1329-40. PubMed ID: 19900016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
    Cooper-DeHoff RM; Aranda JM; Gaxiola E; Cangiano JL; Garcia-Barreto D; Conti CR; Hewkin A; Pepine CJ;
    Am Heart J; 2006 May; 151(5):1072-9. PubMed ID: 16644338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST).
    Ried LD; Tueth MJ; Handberg E; Kupfer S; Pepine CJ;
    Psychosom Med; 2005; 67(3):398-406. PubMed ID: 15911902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of adverse outcome among patients with hypertension and coronary artery disease.
    Pepine CJ; Kowey PR; Kupfer S; Kolloch RE; Benetos A; Mancia G; Coca A; Cooper-DeHoff RM; Handberg E; Gaxiola E; Sleight P; Conti CR; Hewkin AC; Tavazzi L;
    J Am Coll Cardiol; 2006 Feb; 47(3):547-51. PubMed ID: 16458134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
    Cooper-Dehoff R; Cohen JD; Bakris GL; Messerli FH; Erdine S; Hewkin AC; Kupfer S; Pepine CJ;
    Am J Cardiol; 2006 Oct; 98(7):890-4. PubMed ID: 16996868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
    Elliott WJ; Hewkin AC; Kupfer S; Cooper-DeHoff R; Pepine CJ
    J Clin Hypertens (Greenwich); 2005 Nov; 7(11):654-63. PubMed ID: 16278523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
    Kirchengast M
    J Hypertens Suppl; 1997 Mar; 15(2):S27-33. PubMed ID: 9218195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
    JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).
    Winchester DE; Cooper-Dehoff RM; Gong Y; Handberg EM; Pepine CJ;
    Clin Cardiol; 2013 Aug; 36(8):442-7. PubMed ID: 23720247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
    Reynolds NA; Wagstaff AJ; Keam SJ
    Drugs; 2005; 65(13):1893-914. PubMed ID: 16114984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.
    Sharma SK; Ruggenenti P; Remuzzi G
    Vasc Health Risk Manag; 2007; 3(4):453-65. PubMed ID: 17969376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fixed combination of verapamil SR/trandolapril.
    Widimský J
    Expert Opin Pharmacother; 2000 Mar; 1(3):515-35. PubMed ID: 11249535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
    Muijsers RB; Curran MP; Perry CM
    Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.